We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
Analysis of the NRG-GY018 study: pembrolizumab + chemotherapy improved survival in endometrial cancer. Risk of death reduced by 44% in dMMR. Details at ASCO 2026.
